Breaking News

Valeant To Acquire Obagi

March 26, 2013

Professional skin care brand worth $360 million in deal.

Valeant Pharmaceuticals International Inc. has entered into an agreement to acquire Obagi Medical Products Inc. According to reports, Valeant will acquire all the outstanding common stock of Obagi for $19.75 a share in cash, or $360 million.


The professional skin-care company founded by Beverly Hills-based dermatologist Zein Obagi. The Obagi brand, founded in 1988 with the creation of the Obagi Nu-Derm System, is only available through medical professionals. Dr. Obagi sold his controlling interest to outside investors in 1997


At press time, the Obagi board approved the offer, and both companies expect the transaction to be completed in the second quarter of 2013.


  • Patent Activity: Colgate-Palmolive

    Patent Activity: Colgate-Palmolive

    December 6, 2016
    New oral care compositions, the use of radish root ferment filtrate in a cleanser and more.

  • Sparkle & Shine

    Sparkle & Shine

    Melissa Meisel, Associate Editor||November 21, 2016
    Glam packaging and upscale scent combos are big at Yankee Candle for Holiday 2016.

  • Cos Bar: Turning 40 and Hitting Fast Forward

    Cos Bar: Turning 40 and Hitting Fast Forward

    Christine Esposito, Associate Editor||November 21, 2016
    With a recent investor infusion, a new CEO and rebranding effort underway, this luxury beauty retailer has big plans.

  • Slow & Steady

    Slow & Steady

    Tom Branna, Editorial Director||December 1, 2016
    In a tumultuous environment, steady gains posted in the industrial and institutional cleaning sector are welcomed.

  • The World Comes to Orlando

    The World Comes to Orlando

    Tom Branna, Editorial Director||December 1, 2016
    More than 1,600 chemists traveled to Florida for the IFSCC Congress

  • The Plex  Phenomenon

    The Plex Phenomenon

    Denise Costrini, Croda North America||December 1, 2016
    Croda details the hair-protecting qualities of bond multipliers and the company’s new bond-building formulation system.